Joins German firm from Merck & Co bringing therapeutic protein drug development expertise
Laurent Audoly has joined Pieris as chief scientific officer. Audoly, most recently Biologics Research Site Lead at Merck & Co, brings both pharma and biotech experience to the German biotechnology company, particularly expertise in therapeutic protein drug development.
‘Laurent’s pharmacology expertise and drug development skills are the precise ingredients we need to maximise the value of our growing therapeutic pipeline,’ saidd Stephen Yoder, chief executive of Pieris.
‘As the company builds and expands its internal and partnered Anticalin pipeline, Laurent's contribution will be significant.’